Lei Peng
Associate Research Scientist in NeurosurgeryCards
About
Research
Publications
2026
OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
Yang L, Renauer P, Tang K, Saskin J, Zhou L, Zou C, Lee S, Fox M, Johnson-Noya S, Weiss B, Deng S, Fang P, Chen B, Sferruzza G, Fooladi S, Zhao K, Park D, Zhang F, Tu J, Chen J, Moliterno J, Gunel M, Peng L, Chen S. OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Nature 2026, 1-12. PMID: 41741641, DOI: 10.1038/s41586-026-10149-8.Peer-Reviewed Original ResearchCAR-NK cellsCAR-NKSolid tumorsG protein-coupled receptorsOrthotopic breast cancer mouse modelLong-term tumor controlBreast cancer mouse modelCAR-NK therapyPoor tumor infiltrationChemokine receptor expressionCord blood donorsHuman NK cellsCancer mouse modelSolid tumor modelsCRISPR activation screenIn vivo efficacyProtein-coupled receptorsTumor controlTumor infiltrationNK cellsSurvival benefitReceptor expressionPeripheral bloodCell therapyTumor model
2025
A modular vaccine platform for optimized lipid nanoparticle mRNA immunogenicity
Fang Z, Monteiro V, Oh C, Janabi K, Romero L, Ahsan N, Yang L, Peng L, DiMaio D, Lucas C, Chen S. A modular vaccine platform for optimized lipid nanoparticle mRNA immunogenicity. Nature Biomedical Engineering 2025, 10: 501-516. PMID: 40855125, DOI: 10.1038/s41551-025-01478-6.Peer-Reviewed Original ResearchModular vaccine platformCell surface translocationImmune responseMpox virusVaccine platformMRNA vaccinesVaricella zoster virus glycoproteinLethal viral challengeDevelopment of mRNA vaccinesInsufficient immune responseAntigen expressionProteins E6Surface expressionMRNA immunogenicityMultiple cell linesViral challengeAntigenMultiple antigensCell linesAntigenic epitopesChimeric antigenVirus glycoproteinImmunogenicityMRNASurface translocation
2024
Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission
Bai Z, Feng B, McClory S, de Oliveira B, Diorio C, Gregoire C, Tao B, Yang L, Zhao Z, Peng L, Sferruzza G, Zhou L, Zhou X, Kerr J, Baysoy A, Su G, Yang M, Camara P, Chen S, Tang L, June C, Melenhorst J, Grupp S, Fan R. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature 2024, 634: 702-711. PMID: 39322664, PMCID: PMC11485231, DOI: 10.1038/s41586-024-07762-w.Peer-Reviewed Original ResearchChimeric antigen receptorChimeric antigen receptor T cellsT cellsIL-4CAR T-cell dysfunctionChimeric antigen receptor T-cell productsCAR-T cell persistenceProteomic profiling of seraCAR-T cellsT cell persistenceT-cell therapyLong-term remissionT cell dysfunctionCAR-T productsType 2 cytokinesAntigen-specific activationT cell productionAssociated with patientsType 2 cellsDysfunctional subsetPotential therapeutic strategyCellular immunotherapyLeukemia remissionPatients relapseType 2 functionsCAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cellular & Molecular Immunology 2024, 21: 1089-1108. PMID: 39134804, PMCID: PMC11442786, DOI: 10.1038/s41423-024-01207-0.Peer-Reviewed Original ResearchCAR-natural killerCAR-T cellsCAR-TSolid tumorsHematologic malignanciesCell therapyChimeric antigen receptor (CAR)-T cell therapyImmuno-suppressive tumor microenvironmentCAR-T cell therapyCellular cancer immunotherapyRelapsed/refractory hematologic malignanciesCAR-NK cellsTumor traffickingAdoptive immunotherapyCell immunotherapyCellular immunotherapyCancer immunotherapyImmunotherapeutic approachesHLA compatibilityTumor microenvironmentAdult patientsImmunotherapyCombat cancerTumorMalignancyIn vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy
Peng L, Renauer P, Sferruzza G, Yang L, Zou Y, Fang Z, Park J, Chow R, Zhang Y, Lin Q, Bai M, Sanchez A, Zhang Y, Lam S, Ye L, Chen S. In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nature Biotechnology 2024, 43: 752-761. PMID: 38918616, PMCID: PMC11668911, DOI: 10.1038/s41587-024-02282-4.Peer-Reviewed Original ResearchPrimary NK cellsTumor-infiltrating NKCAR-NK cellsNK cellsGenetic checkpointsNatural killerChimeric antigen receptor (CAR)-NK cellsHuman primary NK cellsSolid tumor mouse modelNK cell-based immunotherapyIn vivo antitumor efficacyCAR-NK therapyNK cell therapyCell-based immunotherapyNK cell functionTumor mouse modelTumor infiltrationAntitumor efficacyCell therapyCytokine productionEnhanced cytotoxicityMouse modelSingle-cell transcriptomic landscapeClinical potentialCell function
News
News
Get In Touch
Contacts
Email